The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Key Takeaways Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of NYSE TEVA opened at $17.81 on Thursday. Teva Pharmaceutical Industries has a 12 month low of $11.62 and a 12 month high of $22.80. The company has a market cap of $20.17 billion, a P/E ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

1 Day TEVA 1.97% DJIA 0.02% S&P 500 0.24% Health Care/Life Sciences 0.00% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...